Eckhard Niemeier to head up business at Nouscom

Nouscom, a privately-held immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeier (pictured, above) as its chief business officer (CBO).

He joins the Swiss company from privately-held Danish immunology and infectious diseases specialist UNION Therapeutics, where he also served as CBO and was responsible for all business and corporate development activities, including in- and out-licensing, M&A, and alliance management.

His leadership is described as being instrumental in advancing UNION’s portfolio and corporate strategy. Previously, he held senior roles at Pieris Pharmaceuticals (Nasdaq: PIRS), a US biotech developing immunotherapies to treat respiratory disease and cancer.